Owen Hoare

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Julie Roques · 2 shared papers, 2021 · strength 0.22
   • Paper Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. DOI 10.1016/j.ebiom.2021.103332↗
   • Paper Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. DOI 10.3390/cancers13102473↗
2. Odile Gayet · 2 shared papers, 2021 · strength 0.22
   • Paper Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. DOI 10.1016/j.ebiom.2021.103332↗
   • Paper Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. DOI 10.3390/cancers13102473↗
3. Nicolas Alejandro Fraunhoffer · 2 shared papers, 2021 · strength 0.22
   • Paper Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. DOI 10.1016/j.ebiom.2021.103332↗
   • Paper Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. DOI 10.3390/cancers13102473↗
4. Abdessamad El Kaoutari · 2 shared papers, 2021 · strength 0.22
   • Paper Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. DOI 10.1016/j.ebiom.2021.103332↗
   • Paper Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. DOI 10.3390/cancers13102473↗
5. Juan Iovanna · 2 shared papers, 2021 · strength 0.22
   • Paper Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. DOI 10.1016/j.ebiom.2021.103332↗
   • Paper Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. DOI 10.3390/cancers13102473↗
6. Nelson Dusetti · 2 shared papers, 2021 · strength 0.22
   • Paper Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. DOI 10.1016/j.ebiom.2021.103332↗
   • Paper Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. DOI 10.3390/cancers13102473↗
7. Philippe Soubeyran · 1 shared paper, 2021 · strength 0.12
   • Paper Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. DOI 10.1016/j.ebiom.2021.103332↗
8. Raul A. Urrutia · 1 shared paper, 2021 · strength 0.12
   • Paper Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. DOI 10.1016/j.ebiom.2021.103332↗
9. Gwen Alyce Lomberk · 1 shared paper, 2021 · strength 0.12
   • Paper Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. DOI 10.1016/j.ebiom.2021.103332↗
10. Rémy Nicolle · 1 shared paper, 2021 · strength 0.10
    • Paper Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. DOI 10.3390/cancers13102473↗
11. Sandrine Barbier · 1 shared paper, 2021 · strength 0.10
    • Paper Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. DOI 10.3390/cancers13102473↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.